MarketBeat Launches New FDA Drug Approval Tools to Help Investors Track Key Biotech Catalysts

Sioux Falls, SD – July 23, 2025 – MarketBeat, a trusted source for financial news and data, has officially launched a suite of new tools to help investors stay on top of major FDA-related events that can impact biotech and pharmaceutical stocks. These updates include an enhanced FDA Drug Approval Calendar and dedicated company-specific FDA event pages, giving users a clear view of upcoming drug target dates, including approvals, trial results, and regulatory decisions that often move markets.

_{MarketBeat’s FDA Drug Approval Calendar}

“Our goal is to equip investors with timely, actionable insights,” said Bekah Van Maanen, Web Developer at MarketBeat. “FDA decisions can significantly influence stock performance in biotech and pharma. With our new tools, users can efficiently track these catalysts and integrate this data into their investment research or analysis.”

Key Features of the FDA Drug Approval Calendar

• Tracks a wide range of regulatory events, including:
  • Prescription Drug User Fee Act dates
  • New Drug and Biologics License submissions and reviews
  • Regulatory meeting outcomes
  • Clinical trial data releases
  • Special designations (Breakthrough Therapy, Orphan Drug, RMAT)
• Filter events by company, drug, event type, or date
• View 30-day price changes and real-time market data linked to each event
• Access linked summaries for detailed insights

Company-Specific FDA Event Pages

In addition to the calendar, MarketBeat now offers dedicated FDA event pages for companies with recent or ongoing regulatory activity. These pages include:

• A timeline view of drug development events over the past two years
• Color-coded events to show key milestones at a glance
• Both technical and AI-generated investor-friendly summaries
• Quick links to deeper insights on each regulatory step

_{Timeline view of Eli Lilly and Company drug development}

These tools make it easier than ever for investors to stay ahead of market-moving FDA developments, whether reviewing past outcomes or watching for the next big announcement.

To explore MarketBeat’s FDA Drug Approval Calendar and related tools, visit: www.marketbeat.com/fda-events

About MarketBeat
MarketBeat's mission is to empower individual investors to make better trading decisions by providing real-time financial information and objective market research. With a flagship newsletter, MarketBeat Daily Ratings, reaching over 5 million investors, and a network of financial news websites attracting more than 25 million pageviews monthly, MarketBeat is a trusted source for investment research and insights. The company also offers MarketBeat All Access, a suite of web-based investment research software, furthering its commitment to innovative and accessible investor education. For more information on MarketBeat and its new investment tools, visit marketbeat.com.

Media Relations
Laycee Kluin / MarketBeat
Email: laycee.kluin@marketbeatmail.com